Cartesian Therapeutics Implements Strategic Changes and Grants New Inducement Award
Cartesian Therapeutics, a clinical-stage biotechnology company specializing in mRNA cell therapies for autoimmune diseases, has recently announced significant developments within the company.The approval of the conversion of Series A Convertible Preferred Stock and plans to implement a reverse stock split were approved at the special meeting of stockholders held on March 27, 2024.
In addition to these changes, Cartesian Therapeutics also granted an inducement award to a new employee on March 1, 2024.The employee was issued an option to purchase 375,000 shares of the company’s common stock at an exercise price of $0.69.This option was granted in accordance with the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the board of directors.The option will vest over a period of four years, with full vesting expected on March 1, 2028.
At the time of these announcements, Cartesian Therapeutics Inc.had 132.35 million shares outstanding, with a current price of $0.6242 per share.These strategic changes and inducement awards demonstrate the company’s commitment to growth and innovation in the field of biotechnology.
Comments